ZIB

Treffer pro Seite

Treffer 1 - 2 | 2 Treffer

Sortierung

Digitale Medien

Clinical cardiotoxicity of esorubicin (4′-deoxydoxorubicin,DxDx): Prospective studies with serial gated heart scans and reports of selected cases (1990)

Ringenberg, Q. Scott ; Propert, Kathleen J. ; Muss, Hyman B. ; [weitere]

Springer

Investigational new drugs 8 (1990), S. 221-226

zur Merkliste hinzufügen auf der Merkliste

Details

ISSN: 1573-0646

Schlagwort(e): esorubicin ; 4′-deoxydoxorubicin ; cardiotoxicity ; anthracycline analog

Quelle: Springer Online Journal Archives 1860-2000

Thema: Chemie und Pharmazie , Medizin

Notizen: Summary Esorubicin (4′-deoxydoxorubicin, DxDx) has undergone extensive Phase II investigation for the treatment of cancer. Based on in vitro and animal data, esorubicin may possess less myocardial toxicity when compared to doxorubicin. One hundred thirty-six patients with histologically or cytologically documented non-small cell lung cancer or advanced breast cancer were enrolled in two concurrent CALGB clinical trials using esorubicin at a dose of 30 mg/m2 administered intravenously every 21 days. No patient had previously received an anthracycline agent or had evidence of severe cardiovascular disease. Cardiotoxicity was observed in eleven patients. Four patients developed symptoms of congestive heart failure and three asymptomatic patients had a significant fall in left ventricular ejection fraction (LVEF) as measured by gated pool heart scan. Four patients had cardiac signs or symptoms of indeterminate relationship to esorubicin therapy. Of 44 patients receiving more than four cycles of therapy, 36 patients (82%) had serial gated pool heart scans permitting assessment of subclinical myocardial toxicity. A 5% drop in LVEF was observed following approximately 240 mg/m2 esorubicin; a 10% drop was observed after approximately 480 mg/m2. If further clinical studies are undertaken with esorubicin, investigators are advised to monitor cardiac function frequently once the cumulative esorubicin dose exceeds 240 mg/m2. If congestive failure appears during therapy, prompt cessation of esorubicin and institution of inotropic agents may provide effective palliation. Normal myocardial function may be restored within several months.

Materialart: Digitale Medien

URL: http://dx.doi.org/10.1007/BF00177265

Permalink

Bibliothek	Standort	Signatur	Band/Heft/Jahr	Verfügbarkeit

Andere fanden auch interessant ...

Artikel (Nationallizenzen)

Volltext

Digitale Medien

Metal complexes with tetrapyrrole ligands, LVII. Synthesis, spectra, and structure of nitridorhenium(V) porphyrins (1990)

Buchler, Johann W. ; Cian, André De ; Fischer, Jean ; [weitere]

Weinheim : Wiley-Blackwell

Berichte der deutschen chemischen Gesellschaft 123 (1990), S. 2247-2253

zur Merkliste hinzufügen auf der Merkliste

Details

ISSN: 0009-2940

Schlagwort(e): Rhenium(V) porphyrins ; Nitridorhenium(V) complexes ; Rhenium-Nitrogen triple bonds ; Metalloporphyrins ; Chemistry ; Inorganic Chemistry

Quelle: Wiley InterScience Backfile Collection 1832-2000

Thema: Chemie und Pharmazie

Notizen: Oxorhenium(V) porphyrins ReO(P)X (X = Cl, Br) or [ReO(P)]2O, or trichlororhenium(V) porphyrins ReCl3(P) (P = OEP, TPP, TTP, TAP, TCIP, TMP)2,3, respectively, are transformed into nitridorhenium(V) porphyrins ReN(P) with hydrazine hydrate in the presence of ethanol, in good yields. The diamagnetic complexes are stable towards hydrolysis and contain pentacoordinate ReV in a square pyramid of nitrogen donor atoms. Their structure is deduced spectrometrically and is proven in the case of ReN(OEP) by X-ray crystallography. The UV/Vis- and 1H-NMR spectra of the new nitrido complexes are compared with those of the corresponding zinc(II) porphyrins.

Zusätzliches Material: 3 Ill.